ELAB PMGC Holdings Inc.
USHealthcareAs of 2026-07-09 16:00
Why ELAB matters now
PMGC Holdings Inc. (ELAB) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.06 with +0.00% on the session and $2.1M in market capitalization; recent performance reads 1-month -20.57% and YTD -99.02%.
The latest financial table shown here is Q1 2026, with revenue of $682.0K, net income of $-5.0M, and EPS of $-11.17. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -294.5%.
The latest indexable market news headline is "NorthStrive Biosciences to Advance EL-22 Manufacturing Characterization with Quantitative FACS Analysis of Latent Myostatin Antigen Expression" from GlobeNewsWire.
Additional event context on this page matters because recent insider activity includes Parry Jeffrey filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.05
P/S
2.12
EV/EBITDA
0.41
DCF Value
$-574.25
FCF Yield
-294.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
12.7%
Operating Margin
-746.6%
Net Margin
-873.1%
ROE
-117.0%
ROA
-42.7%
ROIC
-46.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $682.0K | $-5.0M | $-11.17 |
| Q1 2026 | $682.0K | $-5.0M | $-11.17 |
| Q4 2025 | $304.1K | $-3.0M | $-51.92 |
| FY 2025 | $590.1K | $-7.7M | $-378.74 |
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.28
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.